South San Francisco-based Alios BioPharma said Monday that it has raised $41M in a Series B funding round. The funding came from Novo Ventures, SR One, Roche Venture Fund, and Novartis Ventures. A new, undisclosed investor led the round. Alios BioPharma is led by Lawrence M. Blatt, Ph.D. The company is developing antiviral drugs, initially aimed at influenza and Rhinovirus.